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Free radicalsDietary nitrite and nitrate are important sources of nitric oxide (NO). However, the use of nitrite as an
antihypertensive drug may be limited by increased oxidative stress associated with hypertension. We
evaluated the antihypertensive effects of sodium nitrite given in drinking water for 4 weeks in two-kidney
one-clip (2K1C) hypertensive rats and the effects induced by nitrite on NO bioavailability and oxidative stress.
We found that, even under the increased oxidative stress conditions present in 2K1C hypertension, nitrite
reduced systolic blood pressure in a dose-dependent manner. Whereas treatment with nitrite did not
signiﬁcantly change plasma nitrite concentrations in 2K1C rats, it increased plasma nitrate levels signiﬁcantly.
Surprisingly, nitrite treatment exerted antioxidant effects in both hypertensive and sham-normotensive
control rats. A series of in vitro experiments was carried out to show that the antioxidant effects induced by
nitrite do not involve direct antioxidant effects or xanthine oxidase activity inhibition. Conversely, nitrite
decreased vascular NADPH oxidase activity. Taken together, our results show for the ﬁrst time that nitrite has
antihypertensive effects in 2K1C hypertensive rats, which may be due to its antioxidant properties resulting
from vascular NADPH oxidase activity inhibition.tenegro), tanus@fmrp.usp.br,
vier OA license.© 2011 Elsevier Inc. Open access under the Elsevier OA license.The anions nitrite (NO2−) and nitrate (NO3−) are commonly found in
dietary sources such as meat and vegetables [1]. Although they were
initially described as toxic contaminants in foods [2], this negative view
ascribed to nitrite and nitrate changed signiﬁcantly with improved
understanding of nitric oxide (NO)-related pathways in the 1980 s.
Nitrite and nitrate are now known as products of the L-arginine–NO
synthase pathway [3], which reﬂect endogenous NO synthase activity
[4,5]. Of note, although nitrite and nitrate were initially described as
being deprived of biological effects [3,6], more recent studies showed
that, rather than being inert end products of NO, nitrite and nitrate
can be recycled back to NO [7,8]. The mechanisms involved in nitrite
reduction to NO include pH-dependent reduction in the stomach
[9,10] or reduction by xanthine oxidase [11,12], deoxyhemoglobin
[13], myoglobin [14,15], cytochrome P450 [16], and enzymes of the
mitochondrial respiratory chain [17]. These new pathways leading to
NO formation are now being implicated as alternative, complemen-
tary nitrate–nitrite–NO pathways to the classical NO formation from L-
arginine.Many studies have explored the therapeutic potential of activating
nitrate–nitrite–NO pathways, and relevant biological effects were as-
sociated with nitrite or nitrate, including beneﬁcial effects against
ischemia–reperfusion injury [11,18,19], vasorelaxant properties [20],
pulmonary vasodilator effects [21–23], and antihypertensive effects
in experimental [24–27] and in clinical studies [28–30]. Of relevance
for this study, inorganic nitrate supplementation, as well as a nitrate-
rich meal, reduced blood pressure in healthy humans [28,30], and
these effects were ascribed to nitrate bioconversion to nitrite, which
ultimately generates NO [28,30]. Nevertheless, these studies were
performed in healthy volunteers or normotensive rats. Therefore, it is
not clear whether nitrite could be used in the therapy of hypertension.
Importantly, a major feature of hypertension includes increased vas-
cular oxidative stress [31], which decreases NO bioavailability and also
contributes to the formation of peroxynitrite, a highly oxidant mol-
ecule [32]. Taking into consideration that nitrite can be reduced to NO,
it is possible that increased oxidative stress associated with hyper-
tension may limit the use of nitrite in the therapy of hypertension.
The aim of this study was to examine the possible antihyper-
tensive effects of pharmacological doses of sodium nitrite in two-
kidney, one-clip (2K1C) hypertension, which is an experimental
model widely known to increase oxidative stress. We have also
studied possible antioxidant effects induced by nitrite, as well as
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ﬁrst time that nitrite has antihypertensive properties in 2K1C hyper-
tensive rats. Our ﬁndings support the new idea that nitrite exerts
antioxidant effects by downregulating vascular NADPH oxidase
activity.Materials and methods
Animals and treatments
This study complied with guidelines of the Faculty of Medicine of
Ribeirão Preto, University of São Paulo, and the animals were handled
according to the guiding principles published in the National Institutes
of Health Guide for the Care and Use of Laboratory Animals.Male Wistar
rats (180–200 g) obtained from the colonyat theUniversity of São Paulo
(Ribeirão Preto Campus, Brazil) were maintained on a 12-h light/dark
cycle at room temperature (22–25 °C) with free access to standard rat
chow and water.
2K1Chypertensionwas inducedby clipping the left renal arterywith
a silver clip (0.2 mm) [33]. Sham-operated rats underwent the same
surgical procedure except for the clip placement. Ketamine (100 mg/kg)
and xylazine (10 mg/kg) were used ip to anesthetize the animals.
Treatment with sodium nitrite (or vehicle) was started 2 weeks after
surgery and maintained for 4 weeks. The sham-operated rats were
randomly divided into four groups (n=12/group) andwere treated for
4 weeks with vehicle or increasing concentrations (0.5, 5, and 50mM)
of sodium nitrite in their drinking water (sham+vehicle, sham+
0.5 mM, sham+5mM, and sham+50 mM). Similarly, the 2K1C rats
were randomly divided into four groups (n=12/group) and also were
treated for 4 weeks with vehicle or increasing concentrations (0.5, 5,
and 50 mM) of sodium nitrite in their drinking water (2K1C+vehicle,
2K1C+0.5 mM, 2K1C+5 mM, and 2K1C+50 mM). The drinking
water consumptionwasmonitored daily to estimate thenitrite ingested
and the solutionswere changed every 2 days to avoid nitrate formation.
The calculated mean daily nitrite ingestion resulted in approximately
5.6, 61, and 85 mg/kg of nitrite in the groups treated with 0.5, 5, and
50 mM nitrite in their drinking water, respectively.
Body weight and tail systolic blood pressure (SBP) were assessed
weekly by tail-cuff plethysmography. To minimize the effects of stress
induced by this method on blood pressure measurement, the animals
were trained for a week before surgery.Measurement of plasma NOx (nitrate+nitrite) concentrations
Arterial blood samples were collected in tubes containing hepa-
rin and immediately centrifuged at 1000 g for 3 min. Plasma aliquots
were stored at−70 °C until analyzed. The plasma NOx concentrations
were determined in duplicate by using the Griess reaction as we
described previously [34,35]. Brieﬂy, 40 μl of plasma was incubated
with the same volume of nitrate reductase buffer (0.1 M potassium
phosphate, pH 7.5, containing 1 mM β-nicotinamide adenine dinucle-
otide phosphate, and 2 U/ml nitrate reductase) in individual wells of
a 96-well plate. Sampleswere allowed to incubate overnight at 37 °C in
the dark. Eighty microliters of freshly prepared Griess reagent
(1% sulfanilamide, 0.1% naphthylethylenediamine dihydrochloride in
5% phosphoric acid) was added to each well and the plate was in-
cubated for an additional 15 min at room temperature. A standard
nitrate curvewas obtained by incubating sodiumnitrate (0.2–200 μM)
with the same reductase buffer. We found a strong correlation be-
tween the standard curve measurements of nitrate and nitrite (R=
0.999), and the recovery of nitrite was ~98% (data not shown). The
absorbances were measured at 540 nm using a microplate reader. The
assay results were not signiﬁcantly affected by the presence of plasma
proteins.Measurement of plasma nitrite concentrations
Plasma aliquots were analyzed in duplicate for their nitrite content
using an ozone-based reductive chemiluminescence assay as previ-
ously described [35,36]. Brieﬂy, to measure nitrite concentrations in
plasma, 300 μl of plasma sample was injected into a solution of acid-
iﬁed tri-iodide, purging with nitrogen in-line with a gas-phase
chemiluminescence NO analyzer (Sievers Model 280 NO analyzer,
Boulder, CO, USA). Approximately 8 ml of tri-iodide solution (2 g
potassium iodide and 1.3 g iodine dissolved in 40 ml water with
140 ml acetic acid) was placed in the purge vessel into which plasma
samples were injected. The tri-iodide solution reduces nitrites to
NO gas, which is detected by the NO analyzer. The data were ana-
lyzed using the software Origin Lab 6.1.
Assessment of lipid peroxide and 8-isoprostane levels in plasma
Plasma lipid peroxide levels were determined by measuring
thiobarbituric acid-reactive substances (TBARS) using a ﬂuorimetric
method as previously described [34]. Thismethod requires excitation at
515 nmand emission at 553 nmand uses 1,1,3,3-tetramethoxypropane
as standard [37]. The lipoperoxide levels were expressed in terms of
malondialdehyde (nmol/ml).
To further studyoxidative stress, plasma8-isoprostanes (8-isoPGF2α)
concentrations were measured with commercially available enzyme-
linked immunosorbent assay kits (Cayman Chemical Co., Ann Arbor, MI,
USA), according to the manufacturer's instructions.
Measurement of vascular reactive oxygen species (ROS) production
Superoxide production in the aorta was measured by dihydroethid-
ium (DHE), a ROS-sensitive ﬂuorescent dye. The aortic cryosections
(5 μmthick)were incubated at roomtemperaturewithDHE (10 μmol/L)
for 30 min. Sections were examined by ﬂuorescence microscopy (Leica
Imaging Systems Ltd., Cambridge, UK) and the image was captured
at×400. Red ﬂuorescence from 20 ﬁelds around the vessel were eval-
uated using ImageJ software (http://rsbweb.nih.gov/ij/), as described
before [33]. Some experiments were performed in the absence or
presence of tiron (1 mmol/L), an O2•− scavenger; diphenyliodonium
(DPI; 10 μmol/L), an inhibitor of ﬂavoproteins; apocynin (1 mmol/L), a
nonselective inhibitor of NADPH oxidase; or increasing concentration
of nitrite (0.1, 1, and 10 μM). The readings were performed after
preincubation for 20 min with the inhibitors or nitrite.
Evaluation of possible antioxidant effects of nitrite
To assess possible antioxidant properties of nitrite, we evaluated the
O2•− scavenging capacity of nitrite by using pyrogallol as a source of O2•−
and lucigenin chemiluminescence. Brieﬂy, 50 μl of pyrogallol (24 mM
in 10 mMHCl) was added to 900 μl of Tris–HCl buffer (50 mM, pH 8.2)
containing 5 μM lucigenin. Fifty microliters of vehicle, ascorbic acid
(100 μM ﬁnal), or increasing concentrations of nitrite (0.1 to 100 μM
ﬁnal) were tested using a chemiluminescence reader (Berthold FB12
single-tube luminometer) at 37 °C.
In addition, we used absorption spectroscopy to assess whether
pyrogallol autoxidation is decreasedbynitrite. Pyrogallol spontaneously
autoxidizes, thus generating O2•−, which can be inhibited by superoxide
dismutase or antioxidants. The rate of pyrogallol autoxidation is
measured spectrophotometrically at 420 nm [38]. In brief, we mixed
in a cuvette 100 μl of vehicle or ascorbic acid (100 μM) or nitrite (1 to
100 μM), 150 μl of pyrogallol (24 mM in 10 mM HCl), and 2750 μl of
Tris–HCl buffer (50 mM, pH 8.2). The kinetics readings at 420 nmbegan
immediately and lasted for 7 min at 25 °C. A similar approach was used
to evaluate the possibility that nitrite decreases epinephrine autoxida-
tion, which also generates O2•− that can be scavenged by antioxidants.
Brieﬂy, 100 μl of vehicle, ascorbic acid (100 μM), or nitrite (1 to 100 μM)
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containing 0.1 mM EDTA. The reaction was then initiated by adding
100 μl of epinephrine (10 mMprepared in 10 mMHCl) and the kinetics
readings were performed at 480 nm, as described before [39].In vitro effects of nitrite on lipid peroxidation
We evaluated whether nitrite affects lipid peroxidation. In brief,
under deep urethane anesthesia (1.2 g/kg), untreated rats were
euthanized and their livers were collected and placed on ice. Tissues
were immediately homogenized in cold 10 mM Tris–HCl, pH 7.5 (1/10,
w/v), and the homogenates were centrifuged for 15 min at 3000 rpm.
The supernatants (100 μl) were mixed with freshly prepared FeSO4
(10 μM), in the absence or in the presence of vehicle or increasing
concentrations of nitrite (1, 10, and 100 μM) or quercetin (100 μM) and
then incubated for 1 h at 37 °C. Some experiments were performed
without FeSO4 as controls (basal), and after the incubation period, the
amount of thiobarbituric acid-reactive substances formed was deter-
mined as previously described [40]. The rationale for these experiments
is that iron increases lipid peroxidation in the tissue homogenates,
which can be prevented by antioxidants [41].Assessment of plasma xanthine oxidase activity
Plasma xanthine oxidase activities were measured with a
commercial kit (Amplex red xanthine/xanthine oxidase assay kit;
Molecular Probes, Eugene, OR, USA), following the manufacturer's
instructions.Western blotting analysis for xanthine oxidase
To evaluate the vascular expression of xanthine oxidase, Western
blotting was performed as described previously [42], with primary
antibodies (1:500) directed against xanthine oxidase (sc-20991; Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and the expression was
corrected toβ-actin expression (dilution 1:10.000,MAB1501;Millipore,
Temecula, CA, USA).Measurement of NADPH oxidase activity
NADPH-dependent superoxide production was measured in aortic
rings from all experimental groups. Aortic rings were transferred to
luminescence vials containing 1 ml of Hanks’ buffer, pH 7.2. After
equilibration and background counts, a non-redox-cycling concen-
tration of lucigenin (5 μmol/L) and β-NADPH (12 μmol) was auto-
matically added and the luminescence counts were measured
continuously for 15 min in a Berthold FB12 single-tube luminometer
at 37 °C. Background signals from the aortic rings were subtracted
from the β-NADPH-driven signals and the results were normalized for
the dryweight and reported as lucigenin chemiluminescence/mg of dry
tissue, as described previously [43]. Some experiments were performed
in the absence or presence of PEG–SOD (200 U/ml), a cell-permeative
polyethylene glycol–superoxide dismutase; DPI (10 μmol/L), an inhib-
itor of ﬂavoproteins; apocynin (1 mmol/L), a nonselective inhibitor of
NADPH oxidase; allopurinol (10 μmol/L), a xanthine oxidase inhibitor;
or rotenone (10 μmol/L), a mitochondrial electron transport inhibitor.Drugs and solutions
All drugs and reagents were purchased from Sigma Chemical
Co. (St. Louis, MO, USA) and solutions were prepared immediately
before use.Statistical analysis
The results are expressed as means±SEM. The comparisons
between groups were assessed by two-way analysis of variance using
Bonferroni correction or one-way analysis of variance followed by
Dunnett's multiple comparison tests. A probability value b0.05 was
considered signiﬁcant.
Results
Treatment with sodium nitrite ameliorates 2K1C hypertension in a dose-
dependent manner
Baseline SBP and body weight were similar in all experimental
groups (Figs. 1A and B). Whereas no signiﬁcant changes in SBP were
seen in the sham- and sham-nitrite-treated groups, SBP increased in
the 2K1C groups after the ﬁrst week of the renal artery surgery and
peaked at week 4 in the 2K1C+vehicle group (Fig. 1A). Conversely,
treatment of the 2K1C rats with nitrite induced signiﬁcant decreases
in SBP in all 2K1C-nitrite-treated groups in a dose-dependent manner
(Fig. 1A; Pb0.05).
We found no signiﬁcant differences in body weight when all the
experimental groups were compared (Fig. 1B, PN0.05), except for
both sham and 2K1C groups receiving 50 mM nitrite, which gained
less weight than the other groups (Fig. 1B, Pb0.05). Interestingly, the
average drinking water consumption was 68±11 ml/rat/day in
groups receiving only water or nitrite at 0.5 and 5 mM in the drinking
water. However, we found a 37% lower consumption in the groups of
rats receiving nitrite at 50 mM.
Sodium nitrite treatment restored plasma NOx levels in 2K1C hypertension
We examined whether sodium nitrite could reverse the lower NO
availability in 2K1C hypertension. Signiﬁcantly lower plasma NOx and
nitrite levels were found in the 2K1C+vehicle group compared with
those found in the sham+vehicle group (Pb0.05; Figs. 2A and B,
respectively). Interestingly, nitrite treatment induced no signiﬁcant
increases in plasma nitrite concentrations in either the sham- or the
2K1C-nitrite-treated group (PN0.05; Fig. 2B), although the higher
dose tended to increase plasma nitrite levels in the 2K1C+50 mM
group. Conversely, nitrite treatment induced a dose-dependent in-
crease in the plasma NOx levels in 2K1C hypertensive rats, as shown in
Fig. 2A (Pb0.05). However, signiﬁcant increases in plasma NOx were
found in sham-nitrite-treated rats only with the higher dose (50 mM;
Pb0.05; Fig. 2A).
Sodium nitrite treatment produces relevant antioxidant effects
To evaluate the effects of hypertension and nitrite treatment on
oxidative stress, we used three assays, with two of them assessing
oxidative stress in the plasma. We assessed the lipid peroxide levels
by measuring thiobarbituric acid-reactive substances, and the results
showed increased thiobarbituric acid-reactive substances (expressed
in terms of malondialdehyde; MDA) in the 2K1C+vehicle group
compared with the sham+vehicle group (Pb0.01; Fig. 3A). Interest-
ingly, treatment with sodium nitrite produced antioxidant effects, as
suggested by the signiﬁcantly lower lipid peroxide levels in both
sham- and 2K1C-nitrite-treated rats compared with their respective
controls (sham+vehicle and 2K1C+vehicle group, respectively;
Pb0.01; Fig. 3A). We conﬁrmed these ﬁndings by assessing
the plasma levels of 8-isoprostanes. In parallel with thiobarbituric
acid-reactive substances, we found higher plasma 8-isoprostane
levels in the 2K1C-vehicle-treated hypertensive rats compared with
sham-vehicle-treated rats (Pb0.01; Fig. 3B). In the sham groups,
nitrite treatment reduced 8-isoprostane levels when used at 0.5 and
50 mM (Pb0.05; Fig. 3B), but not at 5 mM concentration (PN0.05;
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Fig. 1. (A) Systolic blood pressure (SBP) measured by tail-cuff method and (B) body weight changes throughout the study period. Nitrite (or vehicle) treatment was started by the
end of week 2. Data are shown as means±SEM (n=12 per group). *Pb0.01 for 2K1C versus all sham groups. †,§,#Pb0.01 versus 2K1C group. £Pb0.05 for both groups versus all
other groups.
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when given at 0.5, 5, or 50 mM concentrations to 2K1C hypertensive
rats (Pb0.05; Fig. 3B).
Nitrite treatment decreases the production of vascular ROS in 2K1C
hypertension
to conﬁrm the effects of hypertension and nitrite treatment on
oxidative stress, we used a third assay.We evaluated ROS production by
using the sensitive probe DHE in aortic slices from the animals. We
found that DHE oxidation was signiﬁcantly increased in the 2K1CVeh
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Treatment of 2K1C rats with nitrite attenuated 2K1C-induced oxida-
tive stress in a dose-dependentmanner (Pb0.05, Figs. 4A and B), and no
effects were found in the sham-nitrite-treated groups.
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pretreatment for 30 min with selective NADPH oxidase inhibitors
apocynin (1 mmol/L) or DPI (10 μmol/L) inhibited the DHE oxidation
(Pb0.05, Fig. 4D).
Nitrite does not have direct antioxidant properties
To examine whether nitrite could exert direct antioxidant effects,
we conducted a series of in vitro experiments addressing any possible
O2•− scavenging property of nitrite. Fig. 5A shows that nitrite was unable
to scavenge O2•− generated from pyrogallol, as assessed by lucigenin
chemiluminescence, even when nitrite was tested at 100 μmol/L
(PN0.05). Conversely, ascorbic acid was tested as a positive control
and it prevented the increases in lucigenin chemiluminescence induced
by pyrogallol (Pb0.05; Fig. 5A).
Further conﬁrming these ﬁndings, nitrite had no effect on iron-
induced increases in lipid peroxidation in liver samples (PN0.05; Fig. 5B),
whereas quercetin, an antioxidant ﬂavonoid used here as a positive
control, blunted such effects (Pb0.05; Fig. 5B).
In addition to these ﬁndings, nitrite was unable to decrease
pyrogallol and epinephrine autoxidation (PN0.05; Figs. 5C and D, re-
spectively), which are processes highly dependent on O2•− generation.
Again, ascorbic acid was used as a positive control and it prevented
both pyrogallol and epinephrine autoxidation (Pb0.05; Figs. 5C and D,
respectively).
Sodium nitrite had small effects on plasma xanthine oxidase activity and
no effects on aortic xanthine oxidase expression
We evaluated plasma xanthine oxidase activity in both sham
normotensive and 2K1C hypertensive rats. As expected, we found
increased plasma xanthine oxidase activity in the 2K1C vehicle group
compared with the sham vehicle group (Pb0.05; Fig. 6A). Whereas
treatment with nitrite induced no changes in xanthine oxidase activity
in the sham groups, we found a small decrease in xanthine oxidase
activity in the 2K1C nitrite 50 mM group (Pb0.05; Fig. 6A).
The analysis of xanthine oxidase expression in the aortas showed a
trend for increased xanthine oxidase expression in 2K1C hypertensive
rats compared with sham animals (PN0.05; Fig. 6B) and no signiﬁcant
effects for nitrite.
Nitrite treatment reduces the NADPHoxidase activity in 2K1C hypertension
Because our results showed that nitrite was unable to exert direct
O2•−-scavenging properties, although it decreased lipid peroxidation
and decreased aortic superoxide levels in 2K1C rats, with only minor
effects on xanthine oxidase activity, we decided to study vascular
NADPH oxidase activity because this is an important pro-oxidantenzyme, especially in hypertension. We measured NADPH oxidase
activity in aortas from all experimental groups using lucigenin
chemiluminescence. Surprisingly, treatment with sodium nitrite
signiﬁcantly decreased NADPH oxidase activity in both sham- and
2K1C-nitrite-treated rats (Pb0.01; Fig. 7A). In a series of control ex-
periments, we showed that the chemiluminescence signal was
suppressed by PEG–SOD and by the nonselective NADPH oxidase
inhibitors DPI and apocynin, thus indicating that the signal was not an
artifact (Pb0.01; Fig. 7B). Finally, the pretreatment of aortic rings
with allopurinol or rotenone had no effect on NADPH-induced super-
oxide production (PN0.05; Fig. 7B), thus suggesting that xanthine
oxidase and mitochondria are not relevant contributors to superoxide
production.
Discussion
The main ﬁndings of this study were: (i) nitrite treatment reduced
SBP of 2K1C hypertensive rats; (ii) nitrite treatment exerts antioxi-
dant effects; and (iii) although nitrite does not have direct antioxidant
properties, it downregulates vascular NADPH oxidase activity. These
data suggest that, despite increased oxidative stress present in hy-
pertension, nitrite exerts relevant antihypertensive effects. These
ﬁndings are consistent with the idea that the overall vascular effects
associated with nitrite may involve antioxidant mechanisms in addi-
tion to its bioconversion to NO.
Several reports have described vasodilator effects produced by
nitrite, which are ascribed to nitrite oxide formation [8]. However, the
effect of nitrite in hypertension has been poorly studied. The ﬁrst
study addressing possible antihypertensive effects of nitrite was
reported by Classen et al. [26]. They found that a single oral dose of
nitrite acutely decreased blood pressure in spontaneously hypertensive
rats (SHR) [26]. Later, the same group showed that nitrite attenuated
further increases in SBP found in SHR [44,45]. Interestingly, nitrite did
not decrease blood pressure in these studies, although it prevented
further increases in blood pressure found in matched controls treated
with water [45]. In parallel with these ﬁndings, Tsuchiya et al. showed
that nitrite attenuated the increases in blood pressure caused by L-
NAME, an inhibitor of NO synthases [46]. In the present study, treat-
ment with nitrite was started 2 weeks after hypertension was induced,
so that we would make sure that the animals were really hyperten-
sive when nitrite treatment was started. Interestingly, we found
signiﬁcant antihypertensive effects after the ﬁrst week of treatment,
and this effect improved with time. To our knowledge, this is the ﬁrst
study clearly showing antihypertensive effects exerted by nitrite in
2K1C hypertensive rats.
We found lower plasma nitrite and NOx levels in the 2K1C+vehicle
group compared with the sham+vehicle group, thus suggesting that
hypertension decreases NO availability. Treatment with nitrite did not
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149M.F. Montenegro et al. / Free Radical Biology & Medicine 51 (2011) 144–152increased nitrite levels in the shamor in the 2K1C nitrite groups, despite
a trend for increased nitrite levels with the higher nitrite dose in the
2K1C+nitrite 50 mM group. Conversely, whereas no changes were
seen in plasma NOx levels in the sham groups, treatment with nitrite
induced dose-dependent increases in plasmaNOx levels in hypertensive
rats. Together, these ﬁndings suggest that nitrite is continuously
converted to nitrate and that supplying more nitrite results only in its
oxidation to nitrate. Indeed, most plasma NOx levels correspond to
nitrate [6,43], and the high concentrations of oxyhemoglobin usually
found in thebloodstreamcaneasily convert nitrite tonitrate [47,48]. The
differences in plasma NOx levels found between normotensive and
hypertensive rats reported here suggest that the kinetic proﬁles of
nitrite/nitrate are different in normotensive versus hypertensive
animals. Further studies assessing nitrate excretion in urine from
normotensive and hypertensive animals are needed. The increases inplasma NOx levels found in hypertensive rats after nitrite treatment, but
not in normotensive rats, may be explained by the fact that 2K1C
hypertensive rats have impaired renal function and therefore lower
renal nitrate clearance, whereas normotensive rats do not have this
alteration.
Our ﬁndings suggest that nitrite may offer some advantages in the
treatment of hypertension compared with other NO-donor drugs,
especially in a context of increased oxidative stress. NO donors may
have toxic effects resulting from the reaction between superoxide
anion and NO released by these drugs, thus forming peroxynitrite
[49]. Our results show that nitrite decreases blood pressure, even in a
context of increased oxidative stress. Indeed, we demonstrated that
nitrite reduced lipid peroxide levels in both sham and 2K1C rats, thus
suggesting antioxidant effects produced by this compound. Further
supporting this idea, we evaluated in situ ROS production in the aortas
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150 M.F. Montenegro et al. / Free Radical Biology & Medicine 51 (2011) 144–152from studied animals. By using the ROS-sensitive probe DHE, we
found that treatment with nitrite decreased aortic DHE oxidation in
2K1C rats, thus conﬁrming antioxidant properties of nitrite treatment.
Interestingly, nitrite itself had no direct effects on the increased aortic
DHE oxidation found in hypertensive rats, as suggested by the lack
of any effects of nitrite in experiments in which we preincubated
aortic slices from sham and 2K1C hypertensive rats with increasing
concentrations of nitrite. Conversely, preincubation of aortas with tiron,
a powerful direct O2•− scavenger, signiﬁcantly reduced DHE oxidation.
Similar results were found when we used the nonselective NADPH
oxidase inhibitors apocynin and DPI. Together, these ﬁndings are con-
sistent with antioxidant effects exerted by nitrite.
To show further evidence that nitrite does not exert direct
antioxidant effects, we used different in vitro experimental approaches
to examine whether nitrite could have any O2•−-scavenging capacity.
Nevertheless, nitrite (even at 100 μM concentration) was unable to
show any antioxidant effects. Moreover, nitrite had no direct effects on
lipid peroxidation. Overall, our results provide strong evidence ruling
out the possibility that nitrite could have direct antioxidant effects.We evaluatedwhether treatmentwith nitrite could inhibit xanthine
oxidase or NADPH oxidase and maybe explain the antioxidant effects
reported above. Both enzymes have been implicated as important pro-
oxidant enzymes contributing to hypertension [32,50,51]. As expected,
we found increased xanthine oxidase activity in 2K1C hypertensive
rats treated with vehicle, and treatment with nitrite induced a small
decrease in xanthine oxidase activity in the 2K1C hypertensive rats
treated with the highest nitrite dose. Importantly, xanthine oxidase can
synthesize nitric oxide from nitrite. If xanthine oxidase promotes nitric
oxide formation from nitrite, it is possible that the increases in xanthine
oxidase activity in hypertension that we and others have reported [42]
can exert beneﬁcial effects rather than it being a deleterious pro-oxidant
enzyme. However, this hypothesis remains to be tested.
In parallel with xanthine oxidase activity, we found increased
NADPH oxidase activity in 2K1C hypertensive rats treated with vehicle.
However, treatment with nitrite signiﬁcantly decreased vascular
NADPH oxidase activity in both sham- and 2K1C-nitrite-treated rats.
These results, together with the lower lipid peroxide levels and de-
creased aortic DHE oxidation in 2K1C rats treated with nitrite, are
Veh
icle
Nit
rite
 0.5
 mM
Nit
rite
 5 m
M
Nit
rite
 50
 mM
Veh
icle
Nit
rite
 0.5
 mM
Nit
rite
 5 m
M
Nit
rite
 50
 mM
0
10
20
30
40
50
*
#
Sham 2K1C
Xa
nt
hi
ne
 O
xi
da
se
 (U
/m
L)
XO
Sham
Vehicle Nitrite
0.5mM
Nitrite
5mM
Nitrite
50mM
2K1C
Vehicle Nitrite
0.5mM
Nitrite
5mM
Veh
icle
Nit
rite
 0.5
 mM
Nit
rite
 5 m
M
Nit
rite
 50
 mM
Veh
icle
Nit
rite
 0.5
 mM
Nit
rite
 5 m
M
Nit
rite
 50
 mM
0.0
0.1
0.2
0.3
0.4
0.5 Sham 2K1C
Xa
nt
hi
ne
  O
xid
as
e 1
50
 K
Da
(β-
Ac
tin
 R
at
io
)
Nitrite
50mM
A B
β-actin
Fig. 6. Activity and expression of xanthine oxidase in all experimental groups. (A) Plasma xanthine oxidase activity. (B) A representativeWestern blotting gel showing the expression
of xanthine oxidase in the aortas from rats and a bar graph showing the densitometric data. β-Actin content was used for normalization. Data are shown as means±SEM (n=10–12
per group for activity and n=6 per group for Western blotting results). *Pb0.05 versus the sham vehicle group. #Pb0.05 versus the 2K1C vehicle group.
151M.F. Montenegro et al. / Free Radical Biology & Medicine 51 (2011) 144–152consistent with the suggestion that nitrite exerts relevant antioxidant
effects by inhibiting vascular NADPH activity. Interestingly, we have
previously shown antioxidant effects exerted by nitrite in an animal
model of acute pulmonary thromboembolism [21,23]. Nitrite infusions
attenuated the pulmonary hypertension caused by acute pulmonary
thromboembolism and this effect was associated with lower lipid per-
oxidation [21,23]. Most importantly, nitrite reduced the production of
superoxide by neutrophils stimulated with phorbol 12-myristate 13-
acetate, an NADPH oxidase activator [21]. Finally, our ﬁndings under-
score the notion that, in addition to its vasodilator properties, nitrite
may have relevant antioxidant effects that contribute to its antihyper-
tensive effects reported here.
Some limitations of our study should be taken into consideration.
First, caution should be taken in interpreting the plasma activity of
xanthine oxidase. Although increased xanthine oxidase expression
has been reported in hypertension [42], we found only a trend for
increased expression. However, the increased xanthine oxidase
activity in vascular tissues could help to explain the effects exerted
by nitrite in this study. Second, in this study, we were unable of deﬁne
precise mechanisms explaining how nitrite inhibits NADPH-inducedVeh
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when the aortic rings are incubated for 30 min with a nonselective NADPH oxidase inhibitor
polyethylene glycol–superoxide dismutase (2K1C+PEG–SOD). However, the xanthine oxida
transport rotenone (2K1C+Rotenone) hadnoeffects. Data are shownasmeans±SEM(n=10p
n.s., nonsigniﬁcant.superoxide production. The molecular mechanism, as well as which
NADPH oxidase isoform is inhibited by nitrite, remains unclear and is
currently under investigation. Third, caution should be taken with
respect to the NADPH inhibitors used here (DPI and apocynin), which
are nonselective. Apocynin may have antioxidant effects rather
than being an NADPH oxidase inhibitor [52]. Finally, it might be
relevant to study methemoglobin formation as a result of nitrite
treatment, particularly when nitrite is used at high doses (50 mM),
possibly explaining why the animals gained less weight with this
dose.
In conclusion, our results show evidence that nitrite has antioxidant
effects, probably explained by NADPH oxidase downregulation. Our
ﬁndings show a new and relevant mechanism for the antihypertensive
properties of nitrite in 2K1C hypertensive rats.
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